Funder: METAvivor
Due Dates (Anticipated): March 2026 (Letter of Intent) | August 2026 (Invited full application & internal portal submission) | December 2026 (Final submission to funder)
Funding Amounts: Up to $200,000 total over 2 years (max $100,000/year; includes up to 5% indirect costs)
Summary: Supports translational and clinical research to improve quality of life or mitigate side effects for those living with metastatic breast cancer.
Key Information: Patient advocate involvement is required in both application and review; applications without actionable interventions will not be considered.